dia, yes, when you're on a roll in the lab your published data lags behind because...well because...the competition is on your heels, and you don't have a publicity MACHINE or elves at your fingertips, and you're better at discovering and playing with electronic gadgets than putting your thoughts into a manuscript.
BMY recognized a better Erbitux and bought it. MEDX Second generation MAB. Same with 2C3.
Bavituximab though is not so much a new generation MAB as a differrent one because it uses an exclusive docking site on the diseased cell, inverted PS. And the spin-offs from examining that discovery (inversion of PS)...are mindboggling.
Bavi is safe. Bavi works. Bavi trials will be financed. It is with finance and science gods now, and will move forward in its many permutations in many different labs in many fiancial hands because a newly discovered and widely needed medical treatment brings out greed and high dollars like you cannot imagine.
AT this point the race is to fully humanized anti-cancer MABS, and BMY/IMCL/MEDX are there. Their relationship cost BMY billions and profited IMCL and MEDX stockholders, although not enough for MEDX "long-sufferers." How about the ROCHE/DNA/AFFITEC/PPHM alliance?
Early phase beauty pageants are over for Bavi safety and evidence of efficacy. The most difficult and risky part is behind us. And here we are off 4% today.
We know Bavi does not cure late-phase cancer. But the effect garners respect. And in early trials its numbers were as good or better than Avastin.
So PPHM, Inc enters another phase, one for which we must change our thinking along with that of company managers. Some of them have to change to. If PPHM science has gained critical mass and velocity (congratulations everyone, espec. Dr. Thorpe);if financing of trials is assured; if our gamble now is "how large the market" for Bavi; then share price should be changing too. Why not?
An infusion of "retail" interest? The untold PPHM story is compelling. And not only the science. That PPHM announced a relationship with Roche, via Affitech, a Roche "holding" company which shares some uncanny similarities to PHHM, with a stockprice of $.20 and knockout humanized MAB pipeline. Smells like a Roche.
Will PPHM ever trade better than a public utility before it is bought out? That's up to us. Dynamite price right now, especially if a buy-out only gets us a 5x multiple. Interesting forces at work. The price could snowball rapidly if PPHM stockholders spread the word. It appears there is an invisible hand guiding the executive suite as it relates to "going public with the PPHM story"...and part of the story is the pounding each rally takes by the the same invisible hand.
AI
